Prolong Pharmaceuticals
15
0
0
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 90/100
33.3%
5 terminated/withdrawn out of 15 trials
66.7%
-19.8% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
Safety Study of PP-007 in Subjects With Acute Ischemic Stroke
Role: lead
ANF-Rho in the Treatment of Chronic Neutropenia
Role: lead
Randomized Phase 2, Dose-finding Efficacy, Safety Study of ANF-RHO™ Versus Neulasta® in Chemotherapy-Induced Neutropenia
Role: lead
A Study of EPEG in Beta Thalassemia Patients
Role: lead
A Study on SANGUINATE™ for the Reduction of Delayed Graft Function in Kidney Transplant Patients
Role: lead
Safety and Pharmacokinetics of SANGUINATE™ in Sickle Cell Disease (SCD) Patients
Role: lead
A Study of SANGUINATE for the Treatment of Vaso-occlusive Crisis (VOC) in Adult Sickle Cell Disease Patients
Role: lead
Study to Assess the Safety and Impact on Humoral Sensitization of SANGUINATE in Patients With End Stage Renal Disease
Role: lead
Study of SANGUINATE™ In the Treatment of Sickle Cell Disease Patients With Vaso-Occlusive Crisis
Role: lead
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
Role: lead
SANGUINATE™ in Sickle Cell Disease Associated Leg Ulcer
Role: lead
Efficacy and Safety of SANGUINATE™ for Reduction of Delayed Graft Function in Patients Receiving a Kidney Transplant
Role: lead
Safety and Effect of SANGUINATE™ Infusion in Patients at Risk of Delayed Cerebral Ischemia (DCI) Following Subarachnoid Hemorrhage (SAH)
Role: lead
An Assessment of the Safety and Pharmacokinetics of Ascending Doses of SANGUINATE™ in Healthy Volunteers.
Role: lead
Study of SANGUINATE™ Versus Hydroxyurea in Sickle Cell Disease (SCD) Patients
Role: lead
All 15 trials loaded